Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Biosimilars At US FDA: Personnel Spending Losing Influence Over Program

Aug 19 2018

• By Derrick Gingery

Down arrow on pavement — • Source: jmettraux

Related Content

The Big Spend-Down: US FDA Eyes $159M Reduction In Carryover User Fees

Apr 08 2018

Biosimilar User Fee Forecast: Unchanged Or Lower In FY 2019, US FDA Says

Jul 31 2018

US FDA Reorg: Centers Will Report Directly To Gottlieb; 'Flattened' Structure Will Make Future Political Transitions Easier

Jul 19 2018

Generic Drug Review Costs Still Largely Non-Personnel Related

Aug 10 2015

Biosimilar User Fee Reboot: Resource Challenges Make FDA Eye New Structure

May 02 2016

US FDA Biosimilar User Fee Collections, Expenditures Hit A High Point In 2017

May 29 2018

Additional Topics

United States Biosimilars Review Pathway Regulation FDA BioPharmaceutical

More from Biosimilars

More from Biosimilars & Generics

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window